ABM - Eventos
Apresentação
2º Highlights do Congresso Americano de Oncologia

.

Temas
  • Módulo Ginecologia
  • Módulo Cabeça e Pescoço
  • Módulo Mama
  • Módulo Gastrointestinal
  • Módulo Pulmão
Local do Evento
Auditório do Hospital São Rafael
Endereço: Av. São Rafael, 2152 - 1º Subsolo - São Marcos Salvador-BA Telefone: (71) 2107-9682
Comissão
Dr. Jadeilton Dias (CEHON)
Dr. Marcos Lyra (HSR)
Programação

19/07/2019 – Sexta-feira 

14:00h – Abertura 
14:10 – 15:20h – Módulo Genitourinário
MODERADOR: Dr Frederico Mascarenhas
14:10 – 14:20h – Abstract ID: 4500 - Title: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study – Dr Thiago Martins
14:20 – 14:30h – Abstract ID: 4508 – Title: Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena atrial with focus on intermediate IMDC – risk population. – Dr André Matos
14:30 – 14:40h – Abstract ID: 5001 – Title: Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 Phase III randomized trial – Dra Elisângela Carvalho
14:40 – 14:50h – Abstract ID: 5006 - Title: First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). – Dra Livia Andrade
14:50 – 15:00h – Abstract ID: 5008 - Title: Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC) – Dr Álvaro Lessa
15:00 – 15:10h – Abstract ID: LBA2 - Title: Overall survival (OS) results of a phase III randomized trial of standardof-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co cooperative group trial – Dra Loana Valença
15:10h – 15:20h – Discussão
 
15:20 – 15:40 – Coffee Break
 
15:40 – 16:30h – Módulo Ginecologia
MODERADOR: Dra. Lygia Tinoco
15:40 – 15:50h – Abstract ID: 5500 - Title: A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial – Dra. Ana Amélia Viana
15:50 – 16:00h – Abstract ID: 5505 - Title: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24. Dr. Thiago Martins
16:00 – 16:10h Abstract ID: 5506 - Title: Olaparib monotherapy versus (vs) chemotherapy for germline BRCAmutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial Dr. Álvaro Lessa
16:10 – 16:20h Abstract ID: 5508 - Title: EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study – Dra. Talita Costa

16:20 a 16:30h – Discussão
 
16:30 a 17:10h – Módulo Cabeça e Pescoço 
MODERADOR: Dra. Thamara Melo
16:30 – 16:40h Abstract ID: 6000 Title: Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) Dra. Eni Devay
16:40 – 16:50h Abstract ID: 6002 Title: TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) Dra. Geila Nuñez
16:50 – 17:00h Abstract 6007 -Title: Neck dissections based on sentinela lymph node navigation versus elective neck dissections in early oral cancers: A randomized, multicenter, non-inferiority trial – Dr. André Leonardo
17:00 – 17:10h – Discussão
 
20/07/19 – Sábado
08:30h – 10:00h – Módulo Mama
MODERADOR: Dr Dyego Nunes
08:30 – 08:40h Abstract ID: 503 - Title: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx Dra. Eni Devay
08:40 – 08:50h Abstract ID: 504 - Title: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM) Dr. Dyego Nunes
08:50 – 09:00h Abstract ID: 1000 - Title: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2              therapies (Tx) Dra. Ana Amelia Viana
09:00 – 09:10h Abstract ID: 1002 - Title: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with = 2 HER2-directed regimens: Findings from the multinational, randomized, phase III      NALA trial Dra. Priscila Doria
09:10h – 09:20h Abstract ID: 1003 - Title: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nabpaclitaxel (nP) in previously untreated locally advanced or          metastatic triple-negative breast cancer (mTNBC) Dra. Livia Andrade
09:20 – 09:30h Abstract ID: LBA1008 - Title: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results  Dra. Geila Nuñez
09:30 – 09:40h Discussão

09:40h – 10:00h Coffee Break
 
10:00 – 11:10h Módulo Gastrointestinal
MODERADOR: Dr. Marcos Lyra
10:00 – 10:10h Abstract ID: 4003 - Title: ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced /             metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Dr. Marcos Lyra
10:10 – 10:20h Abstract ID: 3508 Updated results of TRIBE2,a phase III, randomized strategy sudy by GONO in the first – and second-line treatment of unresectable mCRC Dr. Jadeilton Dias
10:20 – 10:30h Abstract LBA4007: Title: Pembrolizumab with or without chemotherapy versus chemotherapy in advanced G/GEJ adenocarcinoma: the phase 3, KEYNOTE-062 study Dra. Fernanda Ásfora
10:30 – 10:40h Abstract 4004: Results of KEYNOTE-240: phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC) Dr. Igor Blohem
10:40 – 10:50h Abstract 4006: optimizing chemoterapy for frail and elderly patients (pts) with advanced gastroesphageal câncer (aGOAC): The GO2 phase III trial Dra. Thamara Melo
10:50 – 11:00h Abstract ID: LBA4 - Title: Olaparib as maintenance treatment following first-line platinumbased chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial Dr. Ângelo Fontes
11:00 – 11:10h Discussão

11:10 – 12:20h Módulo Pulmão
MODERADOR: Dr Álvaro Lessa
11:10 – 11:20h Abstract ID: 8502 - Title: Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC) – Dra. Priscila Doria
11:20 – 11:30h Abstract ID: 8503 - Title: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3) Dr. Álvaro Lessa
11:30 – 11:40h Abstract ID: 8504 - Title: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study Dra. Fernanda Ásfora
11:40 – 11:50h Abstract ID: 9000 - Title: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor             mutation-positive (EGFRm) metastatic nonsmall cell lung cancer (NSCLC) Dra. Patrícia Borrione
12:00 – 12:10h Abstract 9001 Title: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant nonsmall cell lung cancer (gef vs gef+C) Dra. Lygia Tinoco

12:10 – 12:20h Discussão

Informações

As inscrições serão gratuitas e restritas para: médicos, residentes, enfermeiros e farmacêuticos.
Secretaria Executiva: ABM Eventos 
Rua Baependi, 162 – Ondina
Tel: (71) 2107-9682/2107-9684 – Fax.: 2107-9685
E-mail: abmeventos@abmnet.org.br

Inscrição

Inscrições Gratuitas
Vagas Limitadas!

Para se inscrever  Clique no botão abaixo  para se cadastrar e finalizar sua inscrição.

Promoção
Secretaria Executiva
Apoio
Rua Baependi, Nº 162
Ondina, Salvador - Bahia
CEP: 40170-070
Tel.: 71 2107-9666
2019. ABM. Todos os direitos reservados.
Produzido por: Click Interativo - Agência Digital